• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于风险评分的亚组分层可改善原发性高危非肌肉浸润性膀胱癌患者经尿道膀胱肿瘤切除术后的监测成本。

Risk score-based substratification improves surveillance costs after transurethral resection of bladder tumor in patients with primary high-risk non-muscle-invasive bladder cancer.

机构信息

Department of Urology, Hirosaki University Graduate School of Medicine, 5-Zaifucho, Hirosaki, 036-8562, Japan.

Department of Advanced Blood Purification Therapy, Hirosaki University Graduate School of Medicine, 5-Zaifucho, Hirosaki, 036-8562, Japan.

出版信息

Sci Rep. 2022 Aug 12;12(1):13786. doi: 10.1038/s41598-022-17973-8.

DOI:10.1038/s41598-022-17973-8
PMID:35962127
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9374693/
Abstract

High-risk non-muscle-invasive bladder cancer (NMIBC) has a heterogeneity and intensive surveillances after transurethral resection of bladder tumor (TURBT) are major factors of increased costs. Therefore, we aimed to develop optimized surveillance protocols based on the risk score-based substratifications to improve surveillance costs. We retrospectively evaluated 428 patients with primary high-risk NMIBC who underwent TURBT. Patients were substratified into intra-lower, intra-intermediate, and intra-higher groups or UUT-lower, UUT-intermediate, and UUT-higher groups by summing each of the independent risk factors of intravesical and UUT recurrences, respectively. The optimized surveillance protocols that enhance cost-effectiveness were then developed using real incidences of recurrence after TURBT. The 10-year total surveillance costs were compared between the European Association of Urology (EAU) guidelines-based and optimized surveillance protocols. The Kaplan-Meier curves of intravesical and UUT recurrence-free survivals were clearly separated among the substratified groups. The optimized surveillance protocols promoted a 43% reduction ($487,599) in the 10-year total surveillance cost compared to the EAU guidelines-based surveillance protocol. These results suggest that the optimized surveillance protocols based on risk score-based substratifications could potentially reduce over investigation and improve surveillance costs after TURBT in patients with primary high-risk NMIBC.

摘要

高危非肌肉浸润性膀胱癌(NMIBC)具有异质性,经尿道膀胱肿瘤切除术(TURBT)后进行密集监测是增加成本的主要因素。因此,我们旨在根据风险评分分层制定优化的监测方案,以降低监测成本。我们回顾性评估了 428 例接受 TURBT 的初治高危 NMIBC 患者。患者通过分别累加膀胱和 UUT 复发的独立危险因素,分层为内低组、内中组和内高组,或 UUT 下组、UUT 中组和 UUT 高组。然后使用 TURBT 后实际复发率制定增强成本效益的优化监测方案。比较基于欧洲泌尿外科学会(EAU)指南的监测方案和优化监测方案的 10 年总监测成本。分层组的膀胱和 UUT 无复发生存的 Kaplan-Meier 曲线明显分离。与基于 EAU 指南的监测方案相比,优化监测方案可将 10 年总监测成本降低 43%(487,599 美元)。这些结果表明,基于风险评分分层的优化监测方案可能会减少过度检查,并提高初治高危 NMIBC 患者 TURBT 后的监测成本。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79d2/9374693/4b4c32d74b24/41598_2022_17973_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79d2/9374693/a527372d4c5e/41598_2022_17973_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79d2/9374693/93d32fa50945/41598_2022_17973_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79d2/9374693/150f0ca469f7/41598_2022_17973_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79d2/9374693/4b4c32d74b24/41598_2022_17973_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79d2/9374693/a527372d4c5e/41598_2022_17973_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79d2/9374693/93d32fa50945/41598_2022_17973_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79d2/9374693/150f0ca469f7/41598_2022_17973_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79d2/9374693/4b4c32d74b24/41598_2022_17973_Fig4_HTML.jpg

相似文献

1
Risk score-based substratification improves surveillance costs after transurethral resection of bladder tumor in patients with primary high-risk non-muscle-invasive bladder cancer.基于风险评分的亚组分层可改善原发性高危非肌肉浸润性膀胱癌患者经尿道膀胱肿瘤切除术后的监测成本。
Sci Rep. 2022 Aug 12;12(1):13786. doi: 10.1038/s41598-022-17973-8.
2
Impact of an optimized surveillance protocol based on the European Association of Urology substratification on surveillance costs in patients with primary high-risk non-muscle-invasive bladder cancer.基于欧洲泌尿外科学会分层的优化监测方案对初发高危非肌层浸润性膀胱癌患者监测费用的影响。
PLoS One. 2023 Feb 10;18(2):e0275921. doi: 10.1371/journal.pone.0275921. eCollection 2023.
3
Impact of substratification on predicting oncological outcomes in patients with primary high-risk non-muscle-invasive bladder cancer who underwent transurethral resection of bladder tumor.分层对经尿道膀胱肿瘤切除术治疗的原发性高危非肌肉浸润性膀胱癌患者肿瘤学结局预测的影响。
Urol Oncol. 2020 Oct;38(10):795.e9-795.e17. doi: 10.1016/j.urolonc.2020.04.023. Epub 2020 May 14.
4
Impact on Japanese healthcare economics of photodynamic diagnosis-assisted transurethral resection of bladder tumor for non-muscle invasive bladder cancer: A multicenter retrospective cohort study.光动力诊断辅助经尿道膀胱肿瘤切除术治疗非肌层浸润性膀胱癌对日本医疗经济的影响:一项多中心回顾性队列研究。
Int J Urol. 2023 Dec;30(12):1112-1119. doi: 10.1111/iju.15283. Epub 2023 Aug 22.
5
Preoperative chronic kidney disease predicts poor prognosis in patients with primary non-muscle-invasive bladder cancer who underwent transurethral resection of bladder tumor.术前慢性肾脏病预测行经尿道膀胱肿瘤切除术的原发性非肌肉浸润性膀胱癌患者预后不良。
Urol Oncol. 2020 Aug;38(8):684.e1-684.e8. doi: 10.1016/j.urolonc.2020.02.001. Epub 2020 Mar 20.
6
Intraoperative upper urinary tract cytology examination is a risk factor of upper urinary tract recurrence in patients with non-muscle-invasive bladder cancer.术中上尿路细胞学检查是非肌层浸润性膀胱癌患者上尿路复发的危险因素。
Urol Oncol. 2021 Jan;39(1):75.e9-75.e16. doi: 10.1016/j.urolonc.2020.06.011. Epub 2020 Jul 12.
7
Pathology in repeated transurethral resection of a bladder tumor as a risk factor for prognosis of high-risk non-muscle-invasive bladder cancer.膀胱肿瘤重复经尿道切除术的病理学作为高危非肌层浸润性膀胱癌预后的危险因素
PLoS One. 2017 Dec 15;12(12):e0189354. doi: 10.1371/journal.pone.0189354. eCollection 2017.
8
Significance of Bladder Neck Involvement in Risk Substratification of Intermediate-Risk Non-muscle-invasive Bladder Cancer.膀胱颈侵犯对中危非肌层浸润性膀胱癌风险分层的意义。
Eur Urol Focus. 2021 Mar;7(2):366-372. doi: 10.1016/j.euf.2020.01.006. Epub 2020 Jan 25.
9
Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection.前瞻性评估膀胱影像报告和数据系统(VI-RADS)及其对高危非肌肉浸润性膀胱癌患者重复经尿道切除术候选者管理的临床影响。
Eur Urol. 2020 Jan;77(1):101-109. doi: 10.1016/j.eururo.2019.09.029. Epub 2019 Nov 5.
10
EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.EAU 指南:非肌层浸润性膀胱尿路上皮癌:2016 年更新版。
Eur Urol. 2017 Mar;71(3):447-461. doi: 10.1016/j.eururo.2016.05.041. Epub 2016 Jun 17.

本文引用的文献

1
Liquid biopsy in bladder cancer: State of the art and future perspectives.膀胱癌的液体活检:现状与未来展望。
Crit Rev Oncol Hematol. 2022 Feb;170:103577. doi: 10.1016/j.critrevonc.2022.103577. Epub 2022 Jan 5.
2
Impact of chronic kidney disease on oncological outcomes in patients with high-risk non-muscle-invasive bladder cancer who underwent adjuvant bacillus Calmette-Guérin therapy.慢性肾脏病对高危非肌层浸润性膀胱癌患者行辅助卡介苗治疗后肿瘤学结局的影响。
Urol Oncol. 2021 Mar;39(3):191.e9-191.e16. doi: 10.1016/j.urolonc.2020.06.032. Epub 2020 Jul 23.
3
Urine biopsy technologies: Cancer and beyond.
尿液活检技术:癌症及其他。
Theranostics. 2020 Jun 22;10(17):7872-7888. doi: 10.7150/thno.44634. eCollection 2020.
4
Impact of substratification on predicting oncological outcomes in patients with primary high-risk non-muscle-invasive bladder cancer who underwent transurethral resection of bladder tumor.分层对经尿道膀胱肿瘤切除术治疗的原发性高危非肌肉浸润性膀胱癌患者肿瘤学结局预测的影响。
Urol Oncol. 2020 Oct;38(10):795.e9-795.e17. doi: 10.1016/j.urolonc.2020.04.023. Epub 2020 May 14.
5
Update on the guideline of guidelines: non-muscle-invasive bladder cancer.指南更新:非肌肉浸润性膀胱癌。
BJU Int. 2020 Feb;125(2):197-205. doi: 10.1111/bju.14915. Epub 2019 Nov 1.
6
Practice pattern of non-muscle invasive bladder cancer in Japan, Korea and Taiwan: A Web-based survey.日本、韩国和台湾地区非肌层浸润性膀胱癌的诊疗模式:一项基于网络的调查。
Int J Urol. 2019 Dec;26(12):1121-1127. doi: 10.1111/iju.14105. Epub 2019 Sep 11.
7
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.欧洲泌尿外科学会非肌肉浸润性膀胱癌(TaT1 和原位癌)指南 - 2019 年更新版。
Eur Urol. 2019 Nov;76(5):639-657. doi: 10.1016/j.eururo.2019.08.016. Epub 2019 Aug 20.
8
Predictive biomarkers for drug response in bladder cancer.膀胱癌药物反应的预测生物标志物。
Int J Urol. 2019 Nov;26(11):1044-1053. doi: 10.1111/iju.14082. Epub 2019 Aug 1.
9
Determinants of Guideline-Based Treatment in Patients With cT1 Bladder Cancer.cT1 期膀胱癌患者基于指南的治疗的决定因素。
Clin Genitourin Cancer. 2019 Jun;17(3):e461-e471. doi: 10.1016/j.clgc.2019.01.007. Epub 2019 Jan 19.
10
Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories.评估非肌层浸润性膀胱癌监测的成本:基于风险类别的分析。
World J Urol. 2019 Oct;37(10):2059-2065. doi: 10.1007/s00345-018-2550-x. Epub 2018 Nov 16.